BWGE Programme 2021.Indd
Total Page:16
File Type:pdf, Size:1020Kb
DIGITAL XXXIIIrd EDITION 03 > 05.03.21 A DIGITAL EXPERIENCE Grants & Prizes Video conference 33RD Scientific sessions EDITION Invited lectures Satellite Symposia www.bwge.be| 1 | OverView BGWE 2021 PAVILION 1 PAVILION 2 Room ANTWERP Room BRUSSELS Room GENT Room LIEGE ■ 08.30-10.10 PGC ■ 10.30-12.10 PGC ■ 14.00-15.50 ■ 13.15-14.55 IBD - BIRD PGC WEDNESDAY 03/03 WEDNESDAY ■ 16.05-18.30 ■ 15.15-16.55 IBD - BIRD PGC ■ 17.15-19.20 UltraSound Course ■ 08.30-10.30 ■ 08.30-10.30 ■ 08.30-10.25 BASL - BLIC Case Reports GIREM ■ 9.30-10.00 Brohée Lecture ■ 10.00-10.30 Symposium EISAI/MSD ■ 10.45-12.40 BASL - BLIC ■ 10.45-12.40 ■ 10.45-12.35 Case Reports GIREM ■ 13.00-14.00 BeSPGHAN GA ■ 13.30-15.00 ■ 14.00-14.30 ■ 13.30-14.00 GIREM Symposium ■ 14.00-15.10 Symposium ALNYLAM BeSPGHAN MEDTRONIC ■ 14.30-15.45 ■ 15.10-15.40 ■ 14.00-15.36 BASL - BLIC Symposium BSGIE ABBVIE ■ 15.36-17.15 THURSDAY 04/03 THURSDAY ■ 15.40-16.50 BSGIE BeSPGHAN ■ 08.00-09.00 Symposium MSD ■ 09.00-10.30 ■ 9.00-09.50 BSGIE LIVE BGDO ■ 09.50-10.00 Flash IPSEN ■ 10.00-12.00 ■ 10.00-10.50 Working Group BGDO Digestive ■ 10.50-11.20 Pathology ■ 11.00-12.45 Symposium BSGIE LIVE SERVIER ■ 11.20-12.00 BGDO ■ 12.00-12.10 Flash EISAI/MSD ■ 13.00-15.30 ■ 12.10-12.55 Working Group ■ 13.00-14.00 BGDO Digestive Young BASL FRIDAY 05/03 FRIDAY FRIDAY 05/03 FRIDAY Pathology ■ 14.10-15.10 ■ 14.00-15.00 ■ 14.00-16.00 Young BASL Best of BWGE BPC ■ 15.15-16.30 Young BASL | 2 | PAVILLON 2 PG Course ROOM: GENT 08:30-12:10 - SESSION 1 Moderators : C. Van Kemseke (ULg), H. Piessevaux (UCL) ■ 08:30 Refractory benign esophageal strictures: repeated dilations, stenting, cutting? Christophe Snauwaert (AZ St Jan Brugge/UCL) ■ 08:55 Unexplained vomiting syndromes: cyclic vomiting, rumination syndrome, Functional vomiting, migraine… WEDNESDAY 03/03 WEDNESDAY Jan Tack (KUL) ■ 09:20 Non-variceal upper gastro-intestinal bleeding. Maridi Aerts (VUB) ■ 09:45 Optimising medical treatment in IBD. Edouard Louis (ULG) ■ 10:10 BREAK ■ 10:30 Short bowel syndrome. Nutritional aspects and small bowel transplantation. Tim Vanuytsel (KUL) ■ 10:55 Small intestinal bacterial overgrowth (SIBO). Heiko De Schepper (UZA) ■ 11:20 Metabolic complications of bariatric surgery. Mariana Arvanitakis (ULB) ■ 11:45 Medical treatment of advanced neuro-endocrine tumours. Ivan Borbath (UCL) ■ 12:10 BREAK 13:15-16:55 - SESSION 2 Moderators : I. Colle (ASZ Aalst/UG), P. Roelandt (KUL) ■ 13:15 Auto-immune liver diseases: how application of scores can help in early Stratification. Xavier Verhelst (UG ■ 13:40 NAFLD: from diet to transplantation (and all what is in between). Sven Francque (UZA) ■ 14:05 Management of recurrent idiopathic acute pancreatitis. Pierre Deprez (UCL) ■ 14:30 Anticoagulants/anti-aggregants and therapeutic endoscopy. Arnaud Lemmers (ULB) ■ 14:55 BREAK ■ 15:15 Management of benign biliary and pancreatic strictures. Jean-Philippe Loly (ULg) ■ 15:40 Early diagnosis and treatment of cholangiocarcinoma. Rastislav Kunda (VUB) ■ 16:05 Obstructive defecation: conservative and/or surgical treatment? FRIDAY 05/03 FRIDAY Bart van Geluwe (Kortrijk/KUL) ■ 16:30 Anal fissure: a pain in the ass… Danny De Looze (UG) | 3 | PAVILLON 2 UltraSound Course ROOM: GENT 17:15-19:20 - SESSION Moderators : J. Schouten (AZ Nikolaas, Sint-Niklaas), L. Vonghia (UZ Antwerpen) ■ 17:15 Introduction of the new Belgian ultrasound association. Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas), Luisa Vonghia (UZ Antwerpen) ■ WEDNESDAY 03/03 WEDNESDAY 17:20 Ultrasound features in chronic and acute liver disease. Peter Michielsen (UZ Antwerpen) ■ 17:45 Ultrasound features of gallbladder and bile duct disorders. Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas) ■ 18:10 Benign and malignant liver tumours. Anja Geerts (UZ Gent) ■ 18:30 Contrast-enhanced ultrasound in 2021: ready to use in daily practice? Luisa Vonghia (UZ Antwerpen) ■ 18:55 Closing remarks Jeoffrey Schouten (AZ Nikolaas, Sint-Niklaas), Luisa Vonghia (UZ Antwerpen) PGCPOSTGRADUATE COURSE FRIDAY 05/03 FRIDAY | 4 | PAVILLON 1 IBD-BIRD ROOM: BRUSSELS 14:00-15:50 - SESSION 1 : IBD BASIC Moderators : C. Liefferinckx (ULB Erasme), J. P. Guedelha Sabino (UZ Leuven) ■ 14:00 I01 A discriminative metabolic profile in the sera of Crohn’s disease patients with fibrostenosis. S. Bos (1), M. De Vos (1), P. Hindryckx (2), T. Lobaton (2), L. Vanhaecke (1), D. Laukens (1) / WEDNESDAY 03/03 WEDNESDAY [1] U Gent, [2] UZ Gent ■ 14:05 I02 Magnetization transfer MRI and T2-weighted MRI texture analysis allow non-invasive detection of intestinal fibrosis in a fibrosis-inducing chronic colitis mouse model. S. Bos (1), I. De Kock (2), L. Delrue (2), P. Hindryckx (2), M. De Vos (1), G. Villeirs (2), D. Laukens (1) / [1] U Gent, [2] UZ Gent ■ 14:10 Q&A ■ 14:15 I03 Blood proteins linked to immune tolerance, inflammation and cellular junctions reveal a succession of pathophysiological events preceding the relapse in Crohn’s disease patients stopping infliximab. N. Pierre (1), V. Huynh-Thu (1), M. Allez (2), Y. Bouhnik (3), D. Laharie (4), A. Bourreille (5), J. Colombel (6), M. Meuwis (1), E. Louis (1) / [1] U Liege, [2] Hôpital Saint Louis, Paris, France, [3] Hôpital Beaujon, Paris, France, [4] CHU Bordeaux, France, [5] CHU Hotel Dieu, Nantes, France, [6] Mt. Sinai Icahn School of Medicine, USA ■ 14:20 I04 Early prediction of response to vedolizumab in patients with active Inflammatory Bowel Disease: a prospective real-life multicentre cohort Study. C. De Galan (1), G. Gonzales (1), S. Van Welden (1), S. Tavernier (2), T. Lobaton (2), W. Van Moerkercke (3), B. Strubbe (4), H. Peeters (4), E. Macken (5), M. De Vos (1), D. Laukens (1), P. Hindryckx (2)/ [1] U Gent, [2] UZ Gent, [3] AZ Groeninge, Kortrijk, [4] AZ Sint- Lucas, Gent, [5] U Antwerpen ■ 14:25 Q&A ■ 14:30 Invited Lecture : Stromal cells in the pathogenesis of inflammatory bowel Disease. Michael Scharl (Zurich, Switzerland) ■ 14:45 Invited Lecture : JAK-STAT pathway targeting for the treatment of IBD. Silvio Danese (Milan, Italy) ■ 15:00 Invited Lecture : Transmembrane mucins MUC1 and MUC13 as novel players in mucosal barrier dysfunction in IBD. Annemieke Smet (Antwerp, Belgium) ■ 15:15 Q&A ■ 15:35 I05 Long-term environmental hypoxia does not impact experimental Crohn’s like ileitis. C. De Galan, S. Van Welden, T. Lobaton, P. Hindryckx, M. De Vos, D. Laukens / U Gent ■ 15:40 I06 Potential Role of Epithelial Protein Disulphide Isomerases in Crohn’s Disease Fibrosis. S. Vieujean (1), S. Hu (2), E. Bequet (2), C. Salee (2), C. Massot (2), N. Bletard (1), N. Pierre (2), F. Quesada Calvo (2), D. Baiwir (2), G. Mazzucchelli (2), E. De Pauw (2), C. Coimbra Marques (1), P. Delvenne (1), E. Louis (1), M. Meuwis (2) / [1] CHU Liège, [2] U Liege ■ 15:45 Q&A ■ FRIDAY 05/03 FRIDAY 15:50 BREAK | 5 | PAVILLON 1 IBD-BIRD ROOM: BRUSSELS 16:05-18:30 - SESSION 2 : IBD CLINICAL Moderators : E. Louis (ULg Liège), T. Lobaton Ortega (UZ Gent) ■ 16:05 I07 Ultraproactive therapeutic drug monitoring based on point-of-care testing of infliximab is not superior to reactive drug monitoring in patients with inflammatory bowel disease: 1 year results of a pragmatic clinical trial. P. Bossuyt (1), S. Claeys (2), S. D’haens (1), E. Hoefkens (1), B. Strubbe (1), D. Marichal (2), WEDNESDAY 03/03 WEDNESDAY L. Pouillon (1), H. Peeters (2) / [1] Imelda GI Clinical Research Center, Bonheiden, [2] AZ Sint-Lucas, Gent ■ 16:10 I08 Quality improvement by benchmarking of a core outcome indicator set in inflammatory bowel disease: a multicentric feasibility study. P. Bossuyt (1), D. Baert (2), F. Baert (3), E. Hoefkens (1), I. Huys (2), N. Lembrechts (1), E. Jonckere (3), P. Dewint (2), L. Pouillon (1) / [1] Imelda Hospital, Bonheiden, [2] AZ Maria Middelares, Gent, [3] AZ Delta, Roeselare ■ 16:15 Q&A ■ 16:20 I09 Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit. G. Dewitte, J. Geldof, M. Truyens, T. Lobaton / UZ Gent ■ 16:25 I10 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. B. Verstockt (1), D. Alsoud (2), A. Outtier (1), J. Sabino (1), S. Vermeire (1), G. De Hertogh (1), M. Ferrante (1) / [1] UZ Leuven, [2] KULeuven ■ 16:30 Q&A ■ 16:35 I11 Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study. S. Vermeire (1), B. Feagan (2), E. Loftus Jr (3), S. Danese (4), W. Sandborn (5), T. Ritter (6), R. Mehta (7), U. Seidler (8), F. Seibold (9), I. Beales (10), H. Jong Kim (11), J. Mcnally (12), C. Yun (12), S. Zhao (12), X. Liu (12), C. Tasset (13), R. Besuyen (13), M. Watanabe (14), S. Schreiber (15), G. Rogler (16), T. Hibi (17), L. Peyrin-Biroulet (18)/ [1] UZ Leuven, [2] Western University, London, Canada, [3] Mayo Clinic, Rochester, USA, [4] Humanitas University, Milan, Italy, [5] University of California San Diego (UCSD), USA, [6] GI Alliance, Southlake, USA, [7] Surat Institute of Digestive Science, Gujarat, India, [8] Hannover Medical School, Germany, [9] Seibold & Partner Crohn’s Colitis Center, Bern, Switzerland, [10] Norfolk and Norwich University Hospital, UK, [11] Kyung Hee University Hospital, Seoul, Korea, [12] Gilead Sciences Inc, USA, [13] Galapagos NV, [14] Tokyo Medical and Dental University, Tokyo, Japan, [15] University Medical Center Schleswig-Holstein, Kiel, Germany, [16] University Hospital, Zurich, Switzerland, [17] Kitasato Institute Hospital, Tokyo, Japan, [18] Nancy University Hospital, Vandoeuvre-lès-Nancy, France ■ 16:40 I12 Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately-Severely Active Ulcerative Colitis: Phase 2b/3 SELECTION Study.